4 news items
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company's R&D pipeline includes off
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
. First Quarter 2024 Financial Results R&D expense for the first quarter of 2024 was $7.6 million, compared
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
, quality and durability of the immune response to drive antitumor activity. The Company's R&D pipeline includes off-the-shelf therapeutic cancer
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
ELTX
5 Apr 24
, AMP is built to enhance the magnitude, potency, quality, and durability of the immune response to drive antitumor activity. The Company's R&D pipeline
- Prev
- 1
- Next